MRSA-1-Savara1

There are approximately 30,000 people living with cystic fibrosis in the U.S. Cystic fibrosis is a life-shortening genetic disease characterized by thick, sticky mucus in the lungs and chronic lung infections resulting in gradual loss of lung function. The most prevalent lung pathogen in cystic fibrosis patients is Pseudomonas aeruginosa, which is commonly treated using inhaled antibiotics. In recent years, methicillin-resistant Staphylococcus aureus (MRSA), a bacterium that is resistant to conventional antibiotics (1),  has become increasingly common, with a prevalence of almost 30% of the U.S. cystic fibrosis patient population. Recent publications indicate that cystic fibrosis patients with chronic MRSA infection have more hospitalizations, faster decline in lung function, and reduced life expectancy. (2, 3)

1 Gorwitz RJ et al. Journal of Infectious Diseases. 2008:197:1226-34.
2  Elliott C. Dasenbrook; William Checkley; Christian A. Merlo; Michael W. Konstan; Noah Lechtzin; Michael P. Boyle. Association Between Respiratory Tract Methicillin-Resistant Staphylococcus aureus and Survival in Cystic Fibrosis. JAMA, 2010; 303 (23): 2386-2392

MRSA-2-Savara1
(Dasenbrook et al, reprinted with permission, Copyright © (2010) AMA. All rights reserved.)

Vacomycin is one of most commonly used drugs for the treatment of MRSA infection, but it is available only as an intravenous formulation. Currently there is no approved inhaled therapy for MRSA infection, despite the established practice of treating infections of cystic fibrosis patients directly at the site of infection—the lungs. Developing the first inhaled MRSA-antibiotic, AeroVanc, is Savara’s primary focus.